Epic Sciences, Inc. (“Epic Sciences”), announced today the appointment of Dave Henderson as Epic Sciences’ chief information officer (CIO). Mr. Henderson has more than 20 years of experience in information technologies at companies including Sequenom, Inc., CBS Corporation, and Paramount Pictures Corporation.
“As Epic Sciences is advancing our no cell left behind® platform, we look forward to working with Dave who has extensive experience implementing enterprise solutions for global companies in regulated environments,” said Murali Prahalad, Ph.D., President and CEO of Epic Sciences. “In particular, Dave’s experience in strategic planning, information technology development and production support will be invaluable as we launch laboratory developed diagnostic tests, grow our biopharma and translational research partnerships and eventually develop a portfolio of globally-distributed in vitro diagnostic products.”
“The team at Epic Sciences is advancing an impressive platform to supply critical and actionable insights about the status and therapeutic response of a patient’s cancer across each clinical decision point,” said Mr. Henderson. “This is a tremendous opportunity to contribute to the company’s continued rapid growth as well as help shape a new paradigm for cancer care.”
As CIO for Sequenom, Mr. Henderson was a key member of an executive team that developed a commercialization plan for the company, implementing systems to support its ISO certification, FDA submissions, and laboratory developed diagnostic tests, which enabled Sequenom’s rapid scale up to $162 million in annual revenues. As Vice President, TV Systems Support for Paramount Pictures Corporation, Mr. Henderson provided global operational support for enterprise systems responsible for $1 billion in revenue and was part of the executive team executing various mergers and acquisitions including the merger of Paramount Pictures with CBS Corporation. Mr. Henderson is on the Management Information Systems Advisory Board for San Diego State University, College of Business Administration and an active member of the Society for Information Management.
About Epic Sciences
At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.
We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.
For more information, visit epicsciences.com.
Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., email@example.com,+1.858.344.8091